-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

Benzinga·07/29/2026 18:31:04
Listen to the news
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.